Olaparib for Metastatic Castration-Resistant Prostate Cancer
Source: View publication →
The PROfound trial demonstrated that the PARP inhibitor olaparib significantly improves radiographic progression-free survival and overall survival compared to physician's choice of new hormonal agents in patients with metastatic castration-resistant prostate cancer and alterations in homologous recombination repair genes.
Key Findings
Study Design
Study Limitations
Clinical Significance
The PROfound trial established a new standard of care for molecularly-defined subsets of mCRPC, validating the utility of tumor genomic testing to identify patients eligible for targeted PARP inhibitor therapy after failure of standard hormonal approaches.
Historical Context
Prior to the PROfound trial, standard treatments for mCRPC following new hormonal agent failure were limited, often involving further hormonal manipulation or cytotoxic chemotherapy. PROfound was the first positive phase 3 study of a PARP inhibitor in prostate cancer and the first to prospectively utilize genomic selection to tailor treatment in this patient population.
Guided Discussion
High-yield insights from every perspective
Explain the concept of 'synthetic lethality' as it relates to the use of olaparib in prostate cancer patients with BRCA1 or BRCA2 mutations.
Key Response
Synthetic lethality occurs when the simultaneous loss of two pathways leads to cell death, while the loss of either alone is non-lethal. Olaparib inhibits PARP, an enzyme responsible for repairing single-strand DNA breaks. In cells with BRCA1/2 mutations, the homologous recombination repair (HRR) pathway for double-strand breaks is already defective. The inhibition of PARP leads to the accumulation of double-strand breaks that the cancer cell cannot repair, resulting in apoptosis, while normal cells with functional BRCA genes survive.
A patient with metastatic castration-resistant prostate cancer (mCRPC) has progressed on abiraterone. According to the PROfound trial, what diagnostic step is mandatory before initiating olaparib?
Key Response
The trial demonstrated benefit specifically in patients with alterations in homologous recombination repair (HRR) genes. Therefore, molecular testing (via tumor tissue or liquid biopsy) to identify mutations in genes such as BRCA1, BRCA2, or ATM is required. The trial specifically looked at 15 pre-specified genes, with the strongest evidence for Cohort A (BRCA1, BRCA2, and ATM).
Analyze the outcomes of Cohort B in the PROfound trial compared to Cohort A; how does the gene-specific efficacy impact your management of a patient with a PPP2R2A mutation?
Key Response
While the trial overall was positive, the benefit was driven largely by Cohort A (BRCA1, BRCA2, ATM). Exploratory analyses of Cohort B (which included PPP2R2A and others) showed less pronounced benefit. Specifically, the PPP2R2A subgroup appeared to perform worse with olaparib than with the control, suggesting that not all genes in the pre-specified HRR panel are equally predictive of PARP inhibitor sensitivity.
Despite a high crossover rate (66%) from the control arm to the olaparib arm, the PROfound trial still demonstrated a significant overall survival benefit for Cohort A. What does this suggest about the sequencing of PARP inhibitors versus sequential novel hormonal agents (NHAs)?
Key Response
The survival benefit despite crossover suggests that earlier use of olaparib is superior to delaying its use until after a second NHA. It reinforces the 'NHA-to-NHA' switch (e.g., abiraterone to enzalutamide) as generally ineffective in mCRPC, and positions olaparib as a preferred second-line or third-line option for molecularly selected patients.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The PROfound trial utilized a central prospective screening process for HRR gene alterations. How does the high 'screen failure' rate due to tissue quality or inadequate DNA yield (approx. 31%) impact the interpretation of the study's generalizability and the feasibility of its implementation?
Key Response
High screen failure rates indicate that the trial population may be biased toward patients with more accessible or higher-volume metastatic sites (e.g., bone vs. soft tissue differences in DNA extraction). In clinical practice, this highlights a significant hurdle: the need for high-quality genomic material, which may necessitate repeat biopsies or the validation of circulating tumor DNA (ctDNA) as a reliable alternative to facilitate wider implementation.
Evaluate the choice of 'physician's choice' (abiraterone or enzalutamide) as the control arm in PROfound for patients who had already progressed on one NHA. Does this represent a sufficiently rigorous 'standard of care' comparator?
Key Response
A critical reviewer might argue that the control arm was a 'straw man' because clinical experience and previous data (like the PLATO or CARD trials) suggested that switching from one NHA to another has low efficacy. A more challenging control would have been cabazitaxel chemotherapy, which was proven superior to a second NHA in the CARD trial. This choice of control may have inflated the perceived magnitude of olaparib's benefit.
How do the PROfound trial results specifically influence the NCCN guidelines for mCRPC, and why is the recommendation strength different for BRCA versus other HRR mutations?
Key Response
The NCCN guidelines updated their recommendations to include olaparib as a Category 1 recommendation for patients with BRCA1/2 mutations in the mCRPC setting after NHA failure. However, for other HRR mutations (Cohort B), the evidence is considered less robust (Category 2A/B), reflecting the trial's primary endpoint being met in Cohort A and the heterogeneity of responses seen across the broader 15-gene panel.
Clinical Landscape
Noteworthy Related Trials
TOPARP-A Trial
Tested
Olaparib 400mg twice daily
Population
Metastatic castration-resistant prostate cancer patients with DNA repair defects
Comparator
None (single-arm phase 2)
Endpoint
Confirmed response rate (composite)
TRITON2 Trial
Tested
Rucaparib 600mg twice daily
Population
Metastatic castration-resistant prostate cancer with BRCA1, BRCA2, or ATM alterations
Comparator
None (single-arm phase 2)
Endpoint
Confirmed objective response rate
GALAHAD Trial
Tested
Niraparib 300mg once daily
Population
Metastatic castration-resistant prostate cancer with biallelic DNA repair gene defects
Comparator
None (single-arm phase 2)
Endpoint
Objective response rate
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis